Global Primary Immunodeficiency Therapeutic Market Insights, Forecast to 2028

TABLE OF CONTENTS

1 Report Business Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
  • 1.2.2 Immunoglobulin Replacement Therapy
  • 1.2.3 Stem Cell or Bone Marrow Transplantation
  • 1.2.4 Antibiotic Therapy
  • 1.2.5 Gene Therapy
  • 1.2.6 Others
• 1.3 Market by Application
  • 1.3.1 Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
  • 1.3.2 Antibody Deficiency
  • 1.3.3 Cellular Immunodeficiency
  • 1.3.4 Innate Immune Disorders
  • 1.3.5 Others
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Primary Immunodeficiency Therapeutic Market Perspective (2017-2028)
• 2.2 Primary Immunodeficiency Therapeutic Growth Trends by Region
  • 2.2.1 Primary Immunodeficiency Therapeutic Market Size by Region: 2017 VS 2021 VS 2028
  • 2.2.2 Primary Immunodeficiency Therapeutic Historic Market Size by Region (2017-2022)
  • 2.2.3 Primary Immunodeficiency Therapeutic Forecasted Market Size by Region (2023-2028)
• 2.3 Primary Immunodeficiency Therapeutic Market Dynamics
  • 2.3.1 Primary Immunodeficiency Therapeutic Industry Trends
  • 2.3.2 Primary Immunodeficiency Therapeutic Market Drivers
  • 2.3.3 Primary Immunodeficiency Therapeutic Market Challenges
  • 2.3.4 Primary Immunodeficiency Therapeutic Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Primary Immunodeficiency Therapeutic Players by Revenue
  • 3.1.1 Global Top Primary Immunodeficiency Therapeutic Players by Revenue (2017-2022)
  • 3.1.2 Global Primary Immunodeficiency Therapeutic Revenue Market Share by Players (2017-2022)
• 3.2 Global Primary Immunodeficiency Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.3 Players Covered: Ranking by Primary Immunodeficiency Therapeutic Revenue
• 3.4 Global Primary Immunodeficiency Therapeutic Market Concentration Ratio
  • 3.4.1 Global Primary Immunodeficiency Therapeutic Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Primary Immunodeficiency Therapeutic Revenue in 2021
• 3.5 Primary Immunodeficiency Therapeutic Key Players Head office and Area Served
• 3.6 Key Players Primary Immunodeficiency Therapeutic Product Solution and Service
• 3.7 Date of Enter into Primary Immunodeficiency Therapeutic Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Primary Immunodeficiency Therapeutic Breakdown Data by Type

• 4.1 Global Primary Immunodeficiency Therapeutic Historic Market Size by Type (2017-2022)
• 4.2 Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Type (2023-2028)

5 Primary Immunodeficiency Therapeutic Breakdown Data by Application

• 5.1 Global Primary Immunodeficiency Therapeutic Historic Market Size by Application (2017-2022)
• 5.2 Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Application (2023-2028)

6 North America

• 6.1 North America Primary Immunodeficiency Therapeutic Market Size (2017-2028)
• 6.2 North America Primary Immunodeficiency Therapeutic Market Size by Type
  • 6.2.1 North America Primary Immunodeficiency Therapeutic Market Size by Type (2017-2022)
  • 6.2.2 North America Primary Immunodeficiency Therapeutic Market Size by Type (2023-2028)
  • 6.2.3 North America Primary Immunodeficiency Therapeutic Market Share by Type (2017-2028)
• 6.3 North America Primary Immunodeficiency Therapeutic Market Size by Application
  • 6.3.1 North America Primary Immunodeficiency Therapeutic Market Size by Application (2017-2022)
  • 6.3.2 North America Primary Immunodeficiency Therapeutic Market Size by Application (2023-2028)
  • 6.3.3 North America Primary Immunodeficiency Therapeutic Market Share by Application (2017-2028)
• 6.4 North America Primary Immunodeficiency Therapeutic Market Size by Country
  • 6.4.1 North America Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022)
  • 6.4.2 North America Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028)
  • 6.4.3 United States
  • 6.4.4 Canada

7 Europe

• 7.1 Europe Primary Immunodeficiency Therapeutic Market Size (2017-2028)
• 7.2 Europe Primary Immunodeficiency Therapeutic Market Size by Type
  • 7.2.1 Europe Primary Immunodeficiency Therapeutic Market Size by Type (2017-2022)
  • 7.2.2 Europe Primary Immunodeficiency Therapeutic Market Size by Type (2023-2028)
  • 7.2.3 Europe Primary Immunodeficiency Therapeutic Market Share by Type (2017-2028)
• 7.3 Europe Primary Immunodeficiency Therapeutic Market Size by Application
  • 7.3.1 Europe Primary Immunodeficiency Therapeutic Market Size by Application (2017-2022)
  • 7.3.2 Europe Primary Immunodeficiency Therapeutic Market Size by Application (2023-2028)
  • 7.3.3 Europe Primary Immunodeficiency Therapeutic Market Share by Application (2017-2028)
• 7.4 Europe Primary Immunodeficiency Therapeutic Market Size by Country
  • 7.4.1 Europe Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022)
  • 7.4.2 Europe Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic Countries

8 Asia-Pacific

• 8.1 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size (2017-2028)
• 8.2 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Type
  • 8.2.1 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Type (2017-2022)
  • 8.2.2 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Type (2023-2028)
  • 8.2.3 Asia-Pacific Primary Immunodeficiency Therapeutic Market Share by Type (2017-2028)
• 8.3 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Application
  • 8.3.1 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Application (2017-2022)
  • 8.3.2 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Application (2023-2028)
  • 8.3.3 Asia-Pacific Primary Immunodeficiency Therapeutic Market Share by Application (2017-2028)
• 8.4 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region
  • 8.4.1 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2017-2022)
  • 8.4.2 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2023-2028)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Primary Immunodeficiency Therapeutic Market Size (2017-2028)
• 9.2 Latin America Primary Immunodeficiency Therapeutic Market Size by Type
  • 9.2.1 Latin America Primary Immunodeficiency Therapeutic Market Size by Type (2017-2022)
  • 9.2.2 Latin America Primary Immunodeficiency Therapeutic Market Size by Type (2023-2028)
  • 9.2.3 Latin America Primary Immunodeficiency Therapeutic Market Share by Type (2017-2028)
• 9.3 Latin America Primary Immunodeficiency Therapeutic Market Size by Application
  • 9.3.1 Latin America Primary Immunodeficiency Therapeutic Market Size by Application (2017-2022)
  • 9.3.2 Latin America Primary Immunodeficiency Therapeutic Market Size by Application (2023-2028)
  • 9.3.3 Latin America Primary Immunodeficiency Therapeutic Market Share by Application (2017-2028)
• 9.4 Latin America Primary Immunodeficiency Therapeutic Market Size by Country
  • 9.4.1 Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022)
  • 9.4.2 Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size (2017-2028)
• 10.2 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Type
  • 10.2.1 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Type (2017-2022)
  • 10.2.2 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Type (2023-2028)
  • 10.2.3 Middle East & Africa Primary Immunodeficiency Therapeutic Market Share by Type (2017-2028)
• 10.3 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Application
  • 10.3.1 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Application (2017-2022)
  • 10.3.2 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Application (2023-2028)
  • 10.3.3 Middle East & Africa Primary Immunodeficiency Therapeutic Market Share by Application (2017-2028)
• 10.4 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country
  • 10.4.1 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022)
  • 10.4.2 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Baxter International
  • 11.1.1 Baxter International Company Details
  • 11.1.2 Baxter International Business Overview
  • 11.1.3 Baxter International Primary Immunodeficiency Therapeutic Introduction
  • 11.1.4 Baxter International Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
  • 11.1.5 Baxter International Recent Developments
• 11.2 Takeda Pharmaceutical
  • 11.2.1 Takeda Pharmaceutical Company Details
  • 11.2.2 Takeda Pharmaceutical Business Overview
  • 11.2.3 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Introduction
  • 11.2.4 Takeda Pharmaceutical Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
  • 11.2.5 Takeda Pharmaceutical Recent Developments
• 11.3 CSL Limited
  • 11.3.1 CSL Limited Company Details
  • 11.3.2 CSL Limited Business Overview
  • 11.3.3 CSL Limited Primary Immunodeficiency Therapeutic Introduction
  • 11.3.4 CSL Limited Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
  • 11.3.5 CSL Limited Recent Developments
• 11.4 Octapharma
  • 11.4.1 Octapharma Company Details
  • 11.4.2 Octapharma Business Overview
  • 11.4.3 Octapharma Primary Immunodeficiency Therapeutic Introduction
  • 11.4.4 Octapharma Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
  • 11.4.5 Octapharma Recent Developments
• 11.5 Kedrion Biopharma
  • 11.5.1 Kedrion Biopharma Company Details
  • 11.5.2 Kedrion Biopharma Business Overview
  • 11.5.3 Kedrion Biopharma Primary Immunodeficiency Therapeutic Introduction
  • 11.5.4 Kedrion Biopharma Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
  • 11.5.5 Kedrion Biopharma Recent Developments
• 11.6 Bio Products Laboratory
  • 11.6.1 Bio Products Laboratory Company Details
  • 11.6.2 Bio Products Laboratory Business Overview
  • 11.6.3 Bio Products Laboratory Primary Immunodeficiency Therapeutic Introduction
  • 11.6.4 Bio Products Laboratory Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
  • 11.6.5 Bio Products Laboratory Recent Developments
• 11.7 LFB group
  • 11.7.1 LFB group Company Details
  • 11.7.2 LFB group Business Overview
  • 11.7.3 LFB group Primary Immunodeficiency Therapeutic Introduction
  • 11.7.4 LFB group Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
  • 11.7.5 LFB group Recent Developments
• 11.8 Grifols
  • 11.8.1 Grifols Company Details
  • 11.8.2 Grifols Business Overview
  • 11.8.3 Grifols Primary Immunodeficiency Therapeutic Introduction
  • 11.8.4 Grifols Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
  • 11.8.5 Grifols Recent Developments
• 11.9 Lupin Pharmaceuticals
  • 11.9.1 Lupin Pharmaceuticals Company Details
  • 11.9.2 Lupin Pharmaceuticals Business Overview
  • 11.9.3 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Introduction
  • 11.9.4 Lupin Pharmaceuticals Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022)
  • 11.9.5 Lupin Pharmaceuticals Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Author Details
• 13.3 Disclaimer

• Table 1. Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
• Table 2. Key Players of Immunoglobulin Replacement Therapy
• Table 3. Key Players of Stem Cell or Bone Marrow Transplantation
• Table 4. Key Players of Antibiotic Therapy
• Table 5. Key Players of Gene Therapy
• Table 6. Key Players of Others
• Table 7. Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
• Table 8. Global Primary Immunodeficiency Therapeutic Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
• Table 9. Global Primary Immunodeficiency Therapeutic Market Size by Region (2017-2022) & (US$ Million)
• Table 10. Global Primary Immunodeficiency Therapeutic Market Share by Region (2017-2022)
• Table 11. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Region (2023-2028) & (US$ Million)
• Table 12. Global Primary Immunodeficiency Therapeutic Market Share by Region (2023-2028)
• Table 13. Primary Immunodeficiency Therapeutic Market Trends
• Table 14. Primary Immunodeficiency Therapeutic Market Drivers
• Table 15. Primary Immunodeficiency Therapeutic Market Challenges
• Table 16. Primary Immunodeficiency Therapeutic Market Restraints
• Table 17. Global Primary Immunodeficiency Therapeutic Revenue by Players (2017-2022) & (US$ Million)
• Table 18. Global Primary Immunodeficiency Therapeutic Revenue Share by Players (2017-2022)
• Table 19. Global Top Primary Immunodeficiency Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Immunodeficiency Therapeutic as of 2021)
• Table 20. Ranking of Global Top Primary Immunodeficiency Therapeutic Companies by Revenue (US$ Million) in 2021
• Table 21. Global 5 Largest Players Market Share by Primary Immunodeficiency Therapeutic Revenue (CR5 and HHI) & (2017-2022)
• Table 22. Key Players Headquarters and Area Served
• Table 23. Key Players Primary Immunodeficiency Therapeutic Product Solution and Service
• Table 24. Date of Enter into Primary Immunodeficiency Therapeutic Market
• Table 25. Mergers & Acquisitions, Expansion Plans
• Table 26. Global Primary Immunodeficiency Therapeutic Market Size by Type (2017-2022) & (US$ Million)
• Table 27. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2017-2022)
• Table 28. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Type (2023-2028) & (US$ Million)
• Table 29. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2023-2028)
• Table 30. Global Primary Immunodeficiency Therapeutic Market Size by Application (2017-2022) & (US$ Million)
• Table 31. Global Primary Immunodeficiency Therapeutic Revenue Share by Application (2017-2022)
• Table 32. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Application (2023-2028) & (US$ Million)
• Table 33. Global Primary Immunodeficiency Therapeutic Revenue Share by Application (2023-2028)
• Table 34. North America Primary Immunodeficiency Therapeutic Market Size by Type (2017-2022) & (US$ Million)
• Table 35. North America Primary Immunodeficiency Therapeutic Market Size by Type (2023-2028) & (US$ Million)
• Table 36. North America Primary Immunodeficiency Therapeutic Market Size by Application (2017-2022) & (US$ Million)
• Table 37. North America Primary Immunodeficiency Therapeutic Market Size by Application (2023-2028) & (US$ Million)
• Table 38. North America Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022) & (US$ Million)
• Table 39. North America Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028) & (US$ Million)
• Table 40. Europe Primary Immunodeficiency Therapeutic Market Size by Type (2017-2022) & (US$ Million)
• Table 41. Europe Primary Immunodeficiency Therapeutic Market Size by Type (2023-2028) & (US$ Million)
• Table 42. Europe Primary Immunodeficiency Therapeutic Market Size by Application (2017-2022) & (US$ Million)
• Table 43. Europe Primary Immunodeficiency Therapeutic Market Size by Application (2023-2028) & (US$ Million)
• Table 44. Europe Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022) & (US$ Million)
• Table 45. Europe Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028) & (US$ Million)
• Table 46. Asia Pacific Primary Immunodeficiency Therapeutic Market Size by Type (2017-2022) & (US$ Million)
• Table 47. Asia Pacific Primary Immunodeficiency Therapeutic Market Size by Type (2023-2028) & (US$ Million)
• Table 48. Asia Pacific Primary Immunodeficiency Therapeutic Market Size by Application (2017-2022) & (US$ Million)
• Table 49. Asia Pacific Primary Immunodeficiency Therapeutic Market Size by Application (2023-2028) & (US$ Million)
• Table 50. Asia Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2017-2022) & (US$ Million)
• Table 51. Asia Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2023-2028) & (US$ Million)
• Table 52. Latin America Primary Immunodeficiency Therapeutic Market Size by Type (2017-2022) & (US$ Million)
• Table 53. Latin America Primary Immunodeficiency Therapeutic Market Size by Type (2023-2028) & (US$ Million)
• Table 54. Latin America Primary Immunodeficiency Therapeutic Market Size by Application (2017-2022) & (US$ Million)
• Table 55. Latin America Primary Immunodeficiency Therapeutic Market Size by Application (2023-2028) & (US$ Million)
• Table 56. Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022) & (US$ Million)
• Table 57. Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028) & (US$ Million)
• Table 58. Middle East and Africa Primary Immunodeficiency Therapeutic Market Size by Type (2017-2022) & (US$ Million)
• Table 59. Middle East and Africa Primary Immunodeficiency Therapeutic Market Size by Type (2023-2028) & (US$ Million)
• Table 60. Middle East and Africa Primary Immunodeficiency Therapeutic Market Size by Application (2017-2022) & (US$ Million)
• Table 61. Middle East and Africa Primary Immunodeficiency Therapeutic Market Size by Application (2023-2028) & (US$ Million)
• Table 62. Middle East and Africa Primary Immunodeficiency Therapeutic Market Size by Country (2017-2022) & (US$ Million)
• Table 63. Middle East and Africa Primary Immunodeficiency Therapeutic Market Size by Country (2023-2028) & (US$ Million)
• Table 64. Baxter International Company Details
• Table 65. Baxter International Business Overview
• Table 66. Baxter International Primary Immunodeficiency Therapeutic Product
• Table 67. Baxter International Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
• Table 68. Baxter International Recent Developments
• Table 69. Takeda Pharmaceutical Company Details
• Table 70. Takeda Pharmaceutical Business Overview
• Table 71. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Product
• Table 72. Takeda Pharmaceutical Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
• Table 73. Takeda Pharmaceutical Recent Developments
• Table 74. CSL Limited Company Details
• Table 75. CSL Limited Business Overview
• Table 76. CSL Limited Primary Immunodeficiency Therapeutic Product
• Table 77. CSL Limited Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
• Table 78. CSL Limited Recent Developments
• Table 79. Octapharma Company Details
• Table 80. Octapharma Business Overview
• Table 81. Octapharma Primary Immunodeficiency Therapeutic Product
• Table 82. Octapharma Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
• Table 83. Octapharma Recent Developments
• Table 84. Kedrion Biopharma Company Details
• Table 85. Kedrion Biopharma Business Overview
• Table 86. Kedrion Biopharma Primary Immunodeficiency Therapeutic Product
• Table 87. Kedrion Biopharma Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
• Table 88. Kedrion Biopharma Recent Developments
• Table 89. Bio Products Laboratory Company Details
• Table 90. Bio Products Laboratory Business Overview
• Table 91. Bio Products Laboratory Primary Immunodeficiency Therapeutic Product
• Table 92. Bio Products Laboratory Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
• Table 93. Bio Products Laboratory Recent Developments
• Table 94. LFB group Company Details
• Table 95. LFB group Business Overview
• Table 96. LFB group Primary Immunodeficiency Therapeutic Product
• Table 97. LFB group Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
• Table 98. LFB group Recent Developments
• Table 99. Grifols Company Details
• Table 100. Grifols Business Overview
• Table 101. Grifols Primary Immunodeficiency Therapeutic Product
• Table 102. Grifols Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
• Table 103. Grifols Recent Developments
• Table 104. Lupin Pharmaceuticals Company Details
• Table 105. Lupin Pharmaceuticals Business Overview
• Table 106. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Product
• Table 107. Lupin Pharmaceuticals Revenue in Primary Immunodeficiency Therapeutic Business (2017-2022) & (US$ Million)
• Table 108. Lupin Pharmaceuticals Recent Developments
• Table 109. Research Programs/Design for This Report
• Table 110. Key Data Information from Secondary Sources
• Table 111. Key Data Information from Primary Sources

List of Figures

• Figure 1. Global Primary Immunodeficiency Therapeutic Market Share by Type: 2021 VS 2028
• Figure 2. Immunoglobulin Replacement Therapy Features
• Figure 3. Stem Cell or Bone Marrow Transplantation Features
• Figure 4. Antibiotic Therapy Features
• Figure 5. Gene Therapy Features
• Figure 6. Others Features
• Figure 7. Global Primary Immunodeficiency Therapeutic Market Share by Application: 2021 VS 2028
• Figure 8. Antibody Deficiency Case Studies
• Figure 9. Cellular Immunodeficiency Case Studies
• Figure 10. Innate Immune Disorders Case Studies
• Figure 11. Others Case Studies
• Figure 12. Primary Immunodeficiency Therapeutic Report Years Considered
• Figure 13. Global Primary Immunodeficiency Therapeutic Market Size (US$ Million), Year-over-Year: 2017-2028
• Figure 14. Global Primary Immunodeficiency Therapeutic Market Size, (US$ Million), 2017 VS 2021 VS 2028
• Figure 15. Global Primary Immunodeficiency Therapeutic Market Share by Region: 2021 VS 2028
• Figure 16. Global Primary Immunodeficiency Therapeutic Market Share by Players in 2021
• Figure 17. Global Top Primary Immunodeficiency Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Immunodeficiency Therapeutic as of 2021)
• Figure 18. The Top 10 and 5 Players Market Share by Primary Immunodeficiency Therapeutic Revenue in 2021
• Figure 19. North America Primary Immunodeficiency Therapeutic Market Size YoY (2017-2028) & (US$ Million)
• Figure 20. North America Primary Immunodeficiency Therapeutic Market Size Market Share by Type (2017-2028)
• Figure 21. North America Primary Immunodeficiency Therapeutic Market Size Market Share by Application (2017-2028)
• Figure 22. North America Primary Immunodeficiency Therapeutic Market Size Share by Country (2017-2028)
• Figure 23. United States Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 24. Canada Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 25. Europe Primary Immunodeficiency Therapeutic Market Size YoY (2017-2028) & (US$ Million)
• Figure 26. Europe Primary Immunodeficiency Therapeutic Market Size Market Share by Type (2017-2028)
• Figure 27. Europe Primary Immunodeficiency Therapeutic Market Size Market Share by Application (2017-2028)
• Figure 28. Europe Primary Immunodeficiency Therapeutic Market Size Share by Country (2017-2028)
• Figure 29. Germany Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 30. France Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 31. U.K. Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 32. Italy Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 33. Russia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 34. Nordic Countries Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 35. Asia-Pacific Primary Immunodeficiency Therapeutic Market Size YoY (2017-2028) & (US$ Million)
• Figure 36. Asia Pacific Primary Immunodeficiency Therapeutic Market Size Market Share by Type (2017-2028)
• Figure 37. Asia Pacific Primary Immunodeficiency Therapeutic Market Size Market Share by Application (2017-2028)
• Figure 38. Asia Pacific Primary Immunodeficiency Therapeutic Market Size Share by Region (2017-2028)
• Figure 39. China Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 40. Japan Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 41. South Korea Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 42. Southeast Asia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 43. India Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 44. Australia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)

List of Figures

• Figure 45. Latin America Primary Immunodeficiency Therapeutic Market Size YoY (2017-2028) & (US$ Million)
• Figure 46. Latin America Primary Immunodeficiency Therapeutic Market Size Market Share by Type (2017-2028)
• Figure 47. Latin America Primary Immunodeficiency Therapeutic Market Size Market Share by Application (2017-2028)
• Figure 48. Latin America Primary Immunodeficiency Therapeutic Market Size Share by Country (2017-2028)
• Figure 49. Mexico Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 50. Brazil Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 51. Middle East & Africa Primary Immunodeficiency Therapeutic Market Size YoY (2017-2028) & (US$ Million)
• Figure 52. Middle East and Africa Primary Immunodeficiency Therapeutic Market Size Market Share by Type (2017-2028)
• Figure 53. Middle East and Africa Primary Immunodeficiency Therapeutic Market Size Market Share by Application (2017-2028)
• Figure 54. Middle East and Africa Primary Immunodeficiency Therapeutic Market Size Share by Country (2017-2028)
• Figure 55. Turkey Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 56. Saudi Arabia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 57. UAE Primary Immunodeficiency Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 58. Baxter International Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
• Figure 59. Takeda Pharmaceutical Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
• Figure 60. CSL Limited Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
• Figure 61. Octapharma Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
• Figure 62. Kedrion Biopharma Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
• Figure 63. Bio Products Laboratory Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
• Figure 64. LFB group Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
• Figure 65. Grifols Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
• Figure 66. Lupin Pharmaceuticals Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2017-2022)
• Figure 67. Bottom-up and Top-down Approaches for This Report
• Figure 68. Data Triangulation
• Figure 69. Key Executives Interviewed